Physician

Pediatrics

Dr. Karin L. Klingman, MD

Karin L. Klingman works in the field of Pediatrics. Dr. Karin L. Klingman is also a published MD. He has 31 paper published. The most recent paper is: Genetic diversity among strains of Moraxella catarrhalis: analysis using multiple DNA probes and a single-locus PCR-restriction fragment length polymorphism method.

Publications

Depot Medroxyprogesterone Acetate in Combination with a Twice-Daily Lopinavir-Ritonavir-Based Regimen in HIV-Infected Women Showed Effective Contraception and a Lack o...
Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.
Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207.
Greater Suppression of Nevirapine Resistance With 21- vs 7-Day Antiretroviral Regimens After Intrapartum Single-Dose Nevirapine for Prevention of Mother-to-Child Trans...
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: ...
Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5...
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Quality of Life Among Individuals with HIV Starting Antiretroviral Therapy in Diverse Resource-Limited Areas of the World.
Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count.
Immune responses to specific antigens of Streptococcus pneumoniae and Moraxella catarrhalis in the respiratory tract.
CD4+ count-guided interruption of antiretroviral treatment.
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.
Simultaneous respiratory tract colonization by multiple strains of nontypeable haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibi...
Genetic diversity among strains of Moraxella catarrhalis: analysis using multiple DNA probes and a single-locus PCR-restriction fragment length polymorphism method.
Phage antibodies obtained by competitive selection on complement-resistant Moraxella (Branhamella) catarrhalis recognize the high-molecular-weight outer membrane protein.
Purification and characterization of a high-molecular-weight outer membrane protein of Moraxella (Branhamella) catarrhalis.
Dynamics of respiratory tract colonization by Branhamella catarrhalis in bronchiectasis.
Nearest neighbor analysis of outer membrane proteins of nontypeable Haemophilus influenzae.
Diagnosis, epidemiology and pathogenesis of bacterial infections in the molecular era.
Airway inflammation and etiology of acute exacerbations of chronic bronchitis.
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Class-sparing regimens for initial treatment of HIV-1 infection.
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside ...

Schools

State University of New York At Buffalo

Doctors Specialties

Infectious Disease Medicine
Pediatrics

Accepted Insurances

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Larry W. Laughlin, MD This Doctor is OpenDoctor Recommended.
	Dr. Charmagne G. Beckett, MD This Doctor is OpenDoctor Recommended.
	Dr. Henry C. Lane, MD This Doctor is OpenDoctor Recommended.
	Dr. Barney S. Graham, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jeffrey P. Nadler, MD This Doctor is OpenDoctor Recommended.
	Dr. Sebastian W. Lara, MD This Doctor is OpenDoctor Recommended.
	Dr. Danika Alexander, MD This Doctor is OpenDoctor Recommended.
	Dr. Leah T. Enright, MD
	Dr. Marguerite L. Cowtun, MD